News
08-11-2008, 01:40 AM
Geron Corporation (Nasdaq: GERN) announced the enrollment of the first patient in a clinical trial of its telomerase inhibitor drug, GRN163L, in locally recurrent or metastatic breast cancer. The primary objective of the Phase I/II, dose escalation study is to determine the safety, maximum tolerated dose (MTD) and objective response rate of GRN163L when administered intravenously in combination with a paclitaxel/bevacizumab regimen in this patient population.
More... (http://www.medicalnewstoday.com/articles/117733.php)
More... (http://www.medicalnewstoday.com/articles/117733.php)